PFO closure for cryptogenic stroke – Represented in NEJM by the CLOSURE I, PC, REDUCE, CLOSE, and RESPECT trials

26 August 2018 (09:37 - 10:00)

Organised by:

Video

Sign in for access options

Slides

About the speaker

Professor Lars Sondergaard

Rigshospitalet - Copenhagen University Hospital, Copenhagen (Denmark)

3 More presentations in this session

Presentation thumbnail

Antithrombotic therapy in stable cardiovascular disease - Represented in NEJM by the COMPASS trial and the PEGASUS-TIMI 54 trial

Doctor J. Eikelboom (Hamilton, CA)

Presentation thumbnail

Antithrombotic therapy in patients with atrial fibrillation undergoing PCI – Represented in NEJM by the PIONEER-AF PCI trial and the RE-DUAL PCI trial

Professor C. Cannon (Boston, US)

Presentation thumbnail

Fractional Flow Reserve-Guided PCI – represented in NEJM by the FAME, FAME-2, Compare-Acute, IFR-SWEDEHEART, and DEFINE-FLAIR trials

Professor E. Barbato (Rome, IT)

Access the full session

Session thumbnail

Highlights from the New England Journal of Medicine: Editors’ Choice

The Event

ESC Congress 2018

26 August 2018 09:37 CET

You may be interested in

Congress Presentation

Patent foramen ovale in patients above 60 years old

1 September 2025

Congress Presentation

Reporting quality of randomized controlled trials of percutaneous patent foramen ovale closure for the treatment of migraine based on the CONSORT statement

26 August 2023

Congress Presentation

3 September 2019

Congress Presentation

Redefining treatment paradigms for patients with acute pulmonary embolism and patent foramen ovale

1 September 2025

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources